Vestal Point Capital, LP 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Vestal Point Capital, LP disclosed 73 US equity positions worth $1.7bn in its Q4 2024 13F filing. The largest position was JAZZ at 7.1% of the reported book, followed by CYTK and MRK. Against the Q3 2024 filing, it opened 16 new positions, added to 27 and reduced 7 among the top 50 holdings.
What did Vestal Point Capital, LP own in Q4 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | JAZZ Jazz Pharmaceuticals PLC | Healthcare | 7.1% | $120.1m | 975,000 | 8% | added |
| 2 | CYTK Cytokinetics Inc | Healthcare | 6.6% | $110.5m | 2,350,000 | 57% | added |
| 3 | MRK Merck & Co Inc | Healthcare | 4.7% | $79.6m | 800,000 | – | new |
| 4 | ASND Ascendis Pharma A/S | Healthcare | 4.2% | $71.6m | 520,000 | 108% | added |
| 5 | RARE Ultragenyx Pharmaceutical Inc | Healthcare | 3.7% | $63.1m | 1,500,000 | 100% | added |
| 6 | INSM Insmed Inc | Healthcare | 3.7% | $62.1m | 900,000 | -44% | reduced |
| 7 | BMRN BioMarin Pharmaceutical Inc | Healthcare | 3.4% | $56.5m | 860,000 | 115% | added |
| 8 | QURE uniQure NV | 3.2% | $53.4m | 3,025,000 | -36% | reduced | |
| 9 | SLNOEUR Soleno Therapeutics Inc | 2.8% | $47.6m | 1,060,000 | 47% | added | |
| 10 | Nuvalent Inc | 2.8% | $47.0m | 600,000 | – | new | |
| 11 | GPCR Structure Therapeutics Inc | Healthcare | 2.8% | $46.8m | 1,725,000 | 50% | added |
| 12 | VERA Vera Therapeutics Inc | Healthcare | 2.7% | $45.5m | 1,075,000 | – | new |
| 13 | IMTX Immatics NV | Healthcare | 2.6% | $44.6m | 6,275,000 | 67% | added |
| 14 | 4XC1 KalVista Pharmaceuticals Inc | 2.4% | $40.4m | 4,770,000 | 19% | added | |
| 15 | GERN Geron Corp | Healthcare | 2.3% | $38.9m | 11,000,000 | 948% | added |
| 16 | CATBUSD Astria Therapeutics Inc | 2.2% | $37.4m | 4,180,000 | 4% | added | |
| 17 | ACLXGBX Arcellx Inc | 2.2% | $36.4m | 475,000 | -30% | reduced | |
| 18 | SNY Sanofi SA | 2.1% | $36.2m | 750,000 | 400% | added | |
| 19 | GSK GSK PLC | Healthcare | 2.0% | $33.8m | 1,000,000 | 233% | added |
| 20 | SVRA Savara Inc | Healthcare | 2.0% | $33.1m | 10,775,000 | 33% | added |
| 21 | XENE Xenon Pharmaceuticals Inc | Healthcare | 1.9% | $31.8m | 810,000 | -2% | reduced |
| 22 | AM6 Amicus Therapeutics Inc | 1.9% | $31.6m | 3,350,000 | – | new | |
| 23 | AZN AstraZeneca PLC | Healthcare | 1.8% | $31.1m | 475,000 | – | new |
| 24 | SRPT Sarepta Therapeutics Inc | Healthcare | 1.8% | $30.4m | 250,000 | – | new |
| 25 | MDGL Madrigal Pharmaceuticals Inc | Healthcare | 1.7% | $29.3m | 95,000 | 217% | added |
| 26 | GMED Globus Medical Inc | Healthcare | 1.6% | $26.9m | 325,000 | – | new |
| 27 | DNTH Dianthus Therapeutics Inc | Healthcare | 1.4% | $23.4m | 1,075,000 | 172% | added |
| 28 | Nyxoah SA | 1.4% | $23.4m | 2,924,216 | – | new | |
| 29 | VRNA Verona Pharma PLC | 1.4% | $23.0m | 495,000 | – | new | |
| 30 | IONS Ionis Pharmaceuticals Inc | Healthcare | 1.2% | $20.8m | 595,000 | – | new |
| 31 | LQDA Liquidia Corp | Healthcare | 1.2% | $20.7m | 1,760,000 | 17% | added |
| 32 | DAWNGBX Day One Biopharmaceuticals Inc | 1.1% | $18.2m | 1,440,000 | -42% | reduced | |
| 33 | URGN UroGen Pharma Ltd | Healthcare | 1.0% | $17.4m | 1,630,000 | 308% | added |
| 34 | LEGN Legend Biotech Corp | Healthcare | 0.9% | $15.5m | 475,000 | 280% | added |
| 35 | ROIV Roivant Sciences Ltd | Healthcare | 0.9% | $14.8m | 1,250,000 | – | new |
| 36 | REGN Regeneron Pharmaceuticals Inc | Healthcare | 0.8% | $14.2m | 20,000 | – | new |
| 37 | ESTA Establishment Labs Holdings In | Healthcare | 0.8% | $13.8m | 300,000 | 650% | added |
| 38 | TYRA Tyra Biosciences Inc | Healthcare | 0.8% | $13.8m | 990,000 | – | new |
| 39 | BCAX Bicara Therapeutics Inc | 0.7% | $12.4m | 710,000 | 67% | added | |
| 40 | BDTX Black Diamond Therapeutics Inc | 0.7% | $12.0m | 5,600,000 | 11% | added | |
| 41 | SLDB Solid Biosciences Inc | Healthcare | 0.7% | $11.4m | 2,850,000 | 2% | added |
| 42 | A Agilent Technologies Inc | Healthcare | 0.6% | $10.1m | 75,000 | -25% | reduced |
| 43 | APLT Applied Therapeutics Inc | 0.6% | $9.8m | 11,500,000 | 904% | added | |
| 44 | PRGO Perrigo Co PLC | Healthcare | 0.6% | $9.6m | 375,000 | – | new |
| 45 | NRIX Nurix Therapeutics Inc | Healthcare | 0.5% | $9.1m | 485,000 | 14% | added |
| 46 | LXEO Lexeo Therapeutics Inc | Healthcare | 0.5% | $7.9m | 1,200,000 | 41% | added |
| 47 | ZLAB Zai Lab Ltd | Healthcare | 0.5% | $7.9m | 300,000 | – | new |
| 48 | CLDX Celldex Therapeutics Inc | Healthcare | 0.5% | $7.7m | 305,000 | – | new |
| 49 | VYGR Voyager Therapeutics Inc | Healthcare | 0.4% | $7.0m | 1,230,000 | 151% | added |
| 50 | 2662247D iTeos Therapeutics Inc | 0.4% | $6.9m | 900,000 | -12% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.